Hepatitis C care cascades for three populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs.
Academic Article
Overview
Identity
Additional Document Info
View All
Overview
abstract
To achieve elimination of hepatitis C virus (HCV) infection, limited resources can be best allocated through estimation of "care cascades" among groups disproportionately affected. In San Francisco and elsewhere, these groups include young (age ≤30 years) people who inject drugs (YPWID), men who have sex with men who inject drugs (MSM-IDU), and low-income trans women.We developed cross-sectional HCV care cascades for YPWID, MSM-IDU, and trans women using diverse data sources. Population sizes were estimated using an inverse variance-weighted average of estimates from the peer-reviewed literature between 2013-2019. Proportions of past/current HCV infection, diagnosed infection, treatment initiation, and evidence of cure (sustained virologic response at 12 weeks post-treatment) were estimated from the literature using data from seven programs and studies in San Francisco between 2015-2020.The estimated number of YPWID in San Francisco was 3,748; 58.4% had past/current HCV infection, of whom 66.4% were diagnosed with current infection, 9.1% of whom had initiated treatment, and 50% had confirmed cure. The corresponding figures for the 8,135 estimated MSM-IDU were: 29.4% with past/current HCV infection, 70.3% diagnosed with current infection, 28.4% initiated treatment, and 38.9% with confirmed cure. For the estimated 951 low-income trans women, 24.8% had past/current HCV infection, 68.9% were diagnosed with current infection, 56.5% initiated treatment, and 75.5% had confirmed cure.In all three populations, diagnosis rates were relatively high; however, attention is needed to urgently increase treatment initiation in all groups, with particular unmet need among YPWID.© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
publication date
published in
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
number